摘要
Senventy nine advanced cancer patients in a clinical trial were treated with LAK/IL-2 combining with Lycium Barbarum polysaccharides (LBP). Initial results of the treatment from 75 evaluable Patients indicated that objective ragression of cancer was achieved in Patients with malignant melanoma, renal cell carcinoma, colorectal carcinoma, lung caneer, nasophacyngeal carcinoma,malignant hydrothorax. The response rate of patients treated with LAK/IL-2 plus LBP was 40.9% while that of patients treated with LAK/IL-2 was 16.1% (P<0.05).The mean remission duration in Patients treated with LAK/IL-2 Plus LBP also lasted significantly longer.LAK/IL-2 plus LBP treatment led to more marked increase in NK and LAK cell activity than LAK/IL-2without LBP. The results indicated that LBP can be used as an adjuvant in the biotherapy of cancer.
Senventy nine advanced cancer patients in a clinical trial were treated with LAK/IL-2 combining with Lycium Barbarum polysaccharides (LBP). Initial results of the treatment from 75 evaluable Patients indicated that objective ragression of cancer was achieved in Patients with malignant melanoma, renal cell carcinoma, colorectal carcinoma, lung caneer, nasophacyngeal carcinoma,malignant hydrothorax. The response rate of patients treated with LAK/IL-2 plus LBP was 40.9% while that of patients treated with LAK/IL-2 was 16.1% (P<0.05).The mean remission duration in Patients treated with LAK/IL-2 Plus LBP also lasted significantly longer.LAK/IL-2 plus LBP treatment led to more marked increase in NK and LAK cell activity than LAK/IL-2without LBP. The results indicated that LBP can be used as an adjuvant in the biotherapy of cancer.
